ovarian cancer

[Cancer Cell] Investigators showed that tumor-specific CD8+ tumor-infiltrating lymphocytes accumulated in tumor islets, where they engage antigen and upregulate PD-1, which restrained their functions.

[Precigen, Inc.] Precigen, Inc. announced that the US FDA has cleared the Investigational New Drug (IND) application to initiate the Phase I/Ib clinical trial of PRGN-3007 in advanced receptor tyrosine kinase-like orphan receptor 1-positive (ROR1+) hematological and solid tumors.

[npj Breast Cancer] Investigators demonstrated that tumors harboring biallelic RAD51B alteration were deficient in homologous recombination DNA repair deficiency, as evidenced by analysis of sequencing data and in vitro functional assays.

[Journal of Translational Medicine] Programmed death ligand 1 (PD-L1) expression in human ovarian cancer cells after PARP inhibitors treatment was examined by western blotting and flow cytometry.

[T–Cure Bioscience, Inc.] T–Cure Bioscience, Inc. announced that the US FDA has approved the Investigational New Drug application to initiate a Phase I clinical study evaluating a T cell receptor (TCR)–based product candidate for the treatment of tumors expressing Kita–Kyushu lung cancer antigen 1 (KK-LC-1), such as gastric, cervical, lung, breast cancers and other KK–LC–1 positive epithelial cancers.

[npj Breast Cancer] In cell lines, BRCA1 loss was associated with stabilized cyclin E1 during the cell cycle, and BRCA1 siRNA led to increased cyclin E1 in association with reduced phospho-cyclin E1 T62.